The potential for renoprotection with incretin-based drugs

Kidney International

Volumn 86, Issue 4, 2014, Pages 701-711

  Tanaka, Tetsuhiro ^a   Higashijima, Yoshiki ^a   Wada, Takehiko ^a   Nangaku, Masaomi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

diabetes; diabetic nephropathy; DPP 4; GLP 1; incretin

Indexed keywords

ALOGLIPTIN; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; INCRETIN; LINAGLIPTIN; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SODIUM; STROMAL CELL DERIVED FACTOR 1ALPHA; VILDAGLIPTIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR;

ACUTE KIDNEY FAILURE; ANTIHYPERTENSIVE ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DIURESIS; DRUG RECEPTOR BINDING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS CANCER; PANCREATITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PLEIOTROPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL PROTECTION; REVIEW; RHINITIS; SIGNAL TRANSDUCTION; SINUS CONGESTION; SODIUM EXCRETION; VASCULAR ENDOTHELIUM; ACUTE KIDNEY INJURY; AGONISTS; ANIMAL; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DRUG EFFECTS; METABOLISM; RENAL INSUFFICIENCY, CHRONIC;

ACUTE KIDNEY INJURY; ANIMALS; BLOOD PRESSURE; DIABETIC NEPHROPATHIES; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; RECEPTORS, GLUCAGON; RENAL INSUFFICIENCY, CHRONIC; SIGNAL TRANSDUCTION;

EID: 84926197236     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2014.236     Document Type: Review

References (103)

1. Muntner P, Bowling CB, Gao L et al. Age-specific association of reduced estimated glomerular filtration rate and albuminuria with all-cause mortality. Clin J Am Soc Nephrol 2011; 6: 2200-2207.
2. Sharma K, Karl B, Mathew AV et al. Metabolomics reveals signature of mitochondrial dysfunction in diabetic kidney disease. J Am Soc Nephrol 2013; 24: 1901-1912.
3. Baban B, Liu JY, Mozaffari MS. Endoplasmic reticulum stress response and inflammatory cytokines in type 2 diabetic nephropathy: role of indoleamine 2,3-dioxygenase and programmed death-1. Exp Mol Pathol 2013; 94: 343-351.
4. Miyata T, Izuhara Y. Inhibition of advanced glycation end products: an implicit goal in clinical medicine for the treatment of diabetic nephropathy? Ann N Y Acad Sci 2008; 1126: 141-146.
5. Mu J, Pang Q, Guo YH et al. Functional implications of microRNA-215 in TGF-beta1-induced phenotypic transition of mesangial cells by targeting CTNNBIP1. PLoS One 2013; 8: e58622.
6. Deshpande SD, Putta S, Wang M et al. Transforming growth factor-betainduced cross talk between p53 and a microRNA in the pathogenesis of diabetic nephropathy. Diabetes 2013; 62: 3151-3162.
7. Komers R, Mar D, Denisenko O et al. Epigenetic changes in renal genes dysregulated in mouse and rat models of type 1 diabetes. Lab Invest 2013; 93: 543-552.
8. Reddy MA, Sumanth P, Lanting L et al. Losartan reverses permissive epigenetic changes in renal glomeruli of diabetic db/db mice. Kidney Int 2014; 85: 362-373.
9. de Zeeuw D, Akizawa T, Audhya P et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med 2013; 369: 2492-2503.
10. Gaede P, Lund-Andersen H, Parving HH et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591.
11. Nathan DM. The role of glycemia management in the prevention of cardiovascular disease-starting over? Ann Intern Med 2009; 151: 888-889.
12. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
13. Perkovic V, Heerspink HL, Chalmers J et al. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83: 517-523.
14. Nauck MA, Heimesaat MM, Orskov C et al. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 1993; 91: 301-307.
15. Miyawaki K, Yamada Y, Ban N et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002; 8: 738-742.
16. Ozaki N, Shibasaki T, Kashima Y et al. cAMP-GEFII is a direct target of cAMP in regulated exocytosis. Nat Cell Biol 2000; 2: 805-811.
17. Schlatter P, Beglinger C, Drewe J et al. Glucagon-like peptide 1 receptor expression in primary porcine proximal tubular cells. Regul Pept 2007; 141: 120-128.
18. Campos RV, Lee YC, Drucker DJ. Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse. Endocrinology 1994; 134: 2156-2164.
19. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
20. Sivertsen J, Rosenmeier J, Holst JJ et al. The effect of glucagon-like peptide 1 on cardiovascular risk. Nat Rev Cardiol 2012; 9: 209-222.
21. Best JH, Hoogwerf BJ, Herman WH et al. Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database. Diabetes Care 2011; 34: 90-95.
22. Lim SB, Rubinstein I, Sadikot RT et al. A novel peptide nanomedicine against acute lung injury: GLP-1 in phospholipid micelles. Pharm Res 2011; 28: 662-672.
23. Lambeir AM, Durinx C, Scharpe S et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294.
24. Kettmann U, Humbel B, Holzhausen HJ. Ultrastructural localization of dipeptidylpeptidase IV in the glomerulum of the rat kidney. Acta Histochem 1992; 92: 225-227.
25. Stiller D, Bahn H, August C. Demonstration of glomerular DPP IV activity in kidney diseases. Acta Histochem 1991; 91: 105-109.
26. Monami M, Dicembrini I, Martelli D et al. Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials. Curr Med Res Opin 2011; 27(Suppl 3): 57-64.
27. Scirica BM, Bhatt DL, Braunwald E et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013; 369: 1317-1326.
28. White WB, Cannon CP, Heller SR et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013; 369: 1327-1335.
29. Boerrigter G, Costello-Boerrigter LC, Harty GJ et al. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. Am J Physiol Regul Integr Comp Physiol 2007; 292: R897-R901.
30. Hocher B, Sharkovska Y, Mark M et al. The novel DPP-4 inhibitors linagliptin and BI 14361 reduce infarct size after myocardial ischemia/ reperfusion in rats. Int J Cardiol 2013; 167: 87-93.
31. Zhai W, Jungraithmayr W, De Meester I et al. Primary graft dysfunction in lung transplantation: the role of CD26/dipeptidylpeptidase IV and vasoactive intestinal peptide. Transplantation 2009; 87: 1140-1146.
32. Jungraithmayr W, De Meester I, Matheeussen V et al. CD26/DPP-4 inhibition recruits regenerative stem cells via stromal cell-derived factor-1 and beneficially influences ischaemia-reperfusion injury in mouse lung transplantation. Eur J Cardiothorac Surg 2012; 41: 1166-1173.
33. Tagore DM, Nolte WM, Neveu JM et al. Peptidase substrates via global peptide profiling. Nat Chem Biol 2009; 5: 23-25.
34. Bylander J, Li Q, Ramesh G et al. Targeted disruption of the meprin metalloproteinase beta gene protects against renal ischemiareperfusion injury in mice. Am J Physiol Renal Physiol 2008; 294: F480-F490.
35. Boonacker E, Van Noorden CJ. The multifunctional or moonlighting protein CD26/DPPIV. Eur J Cell Biol 2003; 82: 53-73.
36. Tiruppathi C, Ganapathy V, Leibach FH. Evidence for tripeptide-proton symport in renal brush border membrane vesicles. Studies in a novel rat strain with a genetic absence of dipeptidyl peptidase IV. J Biol Chem 1990; 265: 2048-2053.
37. Jost MM, Lamerz J, Tammen H et al. In vivo profiling of DPP4 inhibitors reveals alterations in collagen metabolism and accumulation of an amyloid peptide in rat plasma. Biochem Pharmacol 2009; 77: 228-237.
38. Thielitz A, Vetter RW, Schultze B et al. Inhibitors of dipeptidyl peptidase IV-like activity mediate antifibrotic effects in normal and keloid-derived skin fibroblasts. J Invest Dermatol 2008; 128: 855-866.
39. Jackson EK, Kochanek SJ, Gillespie DG. Dipeptidyl peptidase IV regulates proliferation of preglomerular vascular smooth muscle and mesangial cells. Hypertension 2012; 60: 757-764.
40. Crajoinas RO, Oricchio FT, Pessoa TD et al. Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. Am J Physiol Renal Physiol 2011; 301: F355-F363.
41. Fujita H, Morii T, Fujishima H et al. The protective roles of GLP-1R signaling in diabetic nephropathy: possible mechanism and therapeutic potential. Kidney Int 2014; 85: 579-589.
42. Panjwani N, Mulvihill EE, Longuet C et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology 2013; 154: 127-139.
43. Kirino Y, Sato Y, Kamimoto T et al. Interrelationship of dipeptidyl peptidase IV (DPP4) with the development of diabetes, dyslipidaemia and nephropathy: a streptozotocin-induced model using wild-type and DPP4-deficient rats. J Endocrinol 2009; 200: 53-61.
44. Yang J, Campitelli J, Hu G et al. Increase in DPP-IV in the intestine, liver and kidney of the rat treated with high fat diet and streptozotocin. Life Sci 2007; 81: 272-279.
45. Stefanovic V, Ardaillou N, Vlahovic P et al. Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells. Immunology 1993; 80: 465-470.
46. Mannucci E, Pala L, Ciani S et al. Hyperglycaemia increases dipeptidyl peptidase IV activity in diabetes mellitus. Diabetologia 2005; 48: 1168-1172.
47. Ryskjaer J, Deacon CF, Carr RD et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur J Endocrinol 2006; 155: 485-493.
48. McKillop AM, Duffy NA, Lindsay JR et al. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diabetes Res Clin Pract 2008; 79: 79-85.
49. Liu WJ, Xie SH, Liu YN et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 2012; 340: 248-255.
50. Sun AL, Deng JT, Guan GJ et al. Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease. Diab Vasc Dis Res 2012; 9: 301-308.
51. Mitic B, Lazarevic G, Vlahovic P et al. Diagnostic value of the aminopeptidase N, N-acetyl-beta-D-glucosaminidase and dipeptidylpeptidase IV in evaluating tubular dysfunction in patients with glomerulopathies. Ren Fail 2008; 30: 896-903.
52. Mima A, Hiraoka-Yamomoto J, Li Q et al. Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCbeta activation in diabetes. Diabetes 2012; 61: 2967-2979.
53. Hendarto H, Inoguchi T, Maeda Y et al. GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Metabolism 2012; 61: 1422-1434.
54. Kodera R, Shikata K, Kataoka HU et al. Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
55. Park CW, Kim HW, Ko SH et al. Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
56. Saha S, Li Y, Anand-Srivastava MB. Reduced levels of cyclic AMP contribute to the enhanced oxidative stress in vascular smooth muscle cells from spontaneously hypertensive rats. Can J Physiol Pharmacol 2008; 86: 190-198.
57. Kim JS, Diebold BA, Babior BM et al. Regulation of Nox1 activity via protein kinase A-mediated phosphorylation of NoxA1 and 14-3-3 binding. J Biol Chem 2007; 282: 34787-34800.
58. Ishibashi Y, Nishino Y, Matsui T et al. Glucagon-like peptide-1 suppresses advanced glycation end product-induced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011; 60: 1271-1277.
59. Ojima A, Ishibashi Y, Matsui T et al. Glucagon-like peptide-1 receptor agonist inhibits asymmetric dimethylarginine generation in the kidney of streptozotocin-induced diabetic rats by blocking advanced glycation end product-induced protein arginine methyltranferase-1 expression. Am J Pathol 2013; 182: 132-141.
60. Ishibashi Y, Matsui T, Ojima A et al. Glucagon-like peptide-1 inhibits angiotensin II-induced mesangial cell damage via protein kinase A. Microvasc Res 2012; 84: 395-398.
61. Ta NN, Schuyler CA, Li Y et al. DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice. J Cardiovasc Pharmacol 2011; 58: 157-166.
62. Li W, Cui M, Wei Y et al. Inhibition of the expression of TGF-beta1 and CTGF in human mesangial cells by exendin-4, a glucagon-like peptide-1 receptor agonist. Cell Physiol Biochem 2012; 30: 749-757.
63. Alter ML, Ott IM, von Websky K et al. DPP-4 inhibition on top of angiotensin receptor blockade offers a new therapeutic approach for diabetic nephropathy. Kidney Blood Press Res 2012; 36: 119-130.
64. Mega C, de Lemos ET, Vala H et al. Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011; 2011: 162092.
65. Groop PH, Cooper ME, Perkovic V et al. Linagliptin lowers albuminuria on top of recommended standard treatment in patients with type 2 diabetes and renal dysfunction. Diabetes Care 2013; 36: 3460-3468.
66. Joo KW, Kim S, Ahn SY et al. Dipeptidyl peptidase IV inhibitor attenuates kidney injury in rat remnant kidney. BMC Nephrol 2013; 14: 98.
67. Chaykovska L, Alter ML, von Websky K et al. Effects of telmisartan and linagliptin when used in combination on blood pressure and oxidative stress in rats with 2-kidney-1-clip hypertension. J Hypertens 2013; 31: 2290-2298.
68. Shinosaki T, Kobayashi T, Kimura K et al. Involvement of dipeptidyl peptidase IV in immune complex-mediated glomerulonephritis. Lab Invest 2002; 82: 505-513.
69. Huisamen B, Genis A, Marais E et al. Pre-treatment with a DPP-4 inhibitor is infarct sparing in hearts from obese, pre-diabetic rats. Cardiovasc Drugs Ther 2011; 25: 13-20.
70. Ku HC, Chen WP, Su MJ. GLP-1 signaling preserves cardiac function in endotoxemic Fischer 344 and DPP4-deficient rats. Naunyn Schmiedebergs Arch Pharmacol 2010; 382: 463-474.
71. Ye Y, Keyes KT, Zhang C et al. The myocardial infarct size-limiting effect of sitagliptin is PKA-dependent, whereas the protective effect of pioglitazone is partially dependent on PKA. Am J Physiol Heart Circ Physiol 2010; 298: H1454-H1465.
72. Vaghasiya J, Sheth N, Bhalodia Y et al. Sitagliptin protects renal ischemia reperfusion induced renal damage in diabetes. Regul Pept 2011; 166: 48-54.
73. Glorie LL, Verhulst A, Matheeussen V et al. DPP4 inhibition improves functional outcome after renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2012; 303: F681-F688.
74. Yang H, Li H, Wang Z et al. Exendin-4 ameliorates renal ischemiareperfusion injury in the rat. J Surg Res 2013; 185: 825-832.
75. Katagiri D, Hamasaki Y, Doi K et al. Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. J Am Soc Nephrol 2013; 24: 2034-2043.
76. Toft-Nielsen MB, Madsbad S, Holst JJ. Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 1999; 22: 1137-1143.
77. Astrup A, Rossner S, Van Gaal L et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
78. Moretto TJ, Milton DR, Ridge TD et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther 2008; 30: 1448-1460.
79. Okerson T, Yan P, Stonehouse A et al. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010; 23: 334-339.
80. Apovian CM, Bergenstal RM, Cuddihy RM et al. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. Am J Med 2010; 123: 468.e9-468.e17.
81. Ban K, Noyan-Ashraf MH, Hoefer J et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation 2008; 117: 2340-2350.
82. Nystrom T, Gutniak MK, Zhang Q et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287: E1209-E1215.
83. Thomson SC, Kashkouli A, Singh P. Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. Am J Physiol Renal Physiol 2013; 304: F137-F144.
84. Yu M, Moreno C, Hoagland KM et al. Antihypertensive effect of glucagonlike peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21: 1125-1135.
85. Gutzwiller JP, Hruz P, Huber AR et al. Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans. Digestion 2006; 73: 142-150.
86. Carraro-Lacroix LR, Malnic G, Girardi AC. Regulation of Na/H exchanger NHE3 by glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. Am J Physiol Renal Physiol 2009; 297: F1647-F1655.
87. Hirata K, Kume S, Araki S et al. Exendin-4 has an anti-hypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44-49.
88. Crowley SD, Gurley SB, Herrera MJ et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci USA 2006; 103: 17985-17990.
89. Liu Q, Adams L, Broyde A et al. The exenatide analogue AC3174 attenuates hypertension, insulin resistance, and renal dysfunction in Dahl salt-sensitive rats. Cardiovasc Diabetol 2010; 9: 32.
90. Laugero KD, Stonehouse AH, Guss S et al. Exenatide improves hypertension in a rat model of the metabolic syndrome. Metab Syndr Relat Disord 2009; 7: 327-334.
91. Pacheco BP, Crajoinas RO, Couto GK et al. Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. J Hypertens 2011; 29: 520-528.
92. Ferreira L, Teixeira-de-Lemos E, Pinto F et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediators Inflamm 2010; 2010: 592760.
93. Matsui T, Nishino Y, Takeuchi M et al. Vildagliptin blocks vascular injury in thoracic aorta of diabetic rats by suppressing advanced glycation end product-receptor axis. Pharmacol Res 2011; 63: 383-388.
94. Girardi AC, Fukuda LE, Rossoni LV et al. Dipeptidyl peptidase IV inhibition downregulates Na-H exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol 2008; 294: F414-F422.
95. Girardi AC, Degray BC, Nagy T et al. Association of Na()-H() exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule. J Biol Chem 2001; 276: 46671-46677.
96. Girardi AC, Knauf F, Demuth HU et al. Role of dipeptidyl peptidase IV in regulating activity of Na/H exchanger isoform NHE3 in proximal tubule cells. Am J Physiol Cell Physiol 2004; 287: C1238-C1245.
97. Rieg T, Gerasimova M, Murray F et al. Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice. Am J Physiol Renal Physiol 2012; 303: F963-F971.
98. Kim M, Platt MJ, Shibasaki T et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19: 567-575.
99. Jackson EK, Mi Z. Sitagliptin augments sympathetic enhancement of the renovascular effects of angiotensin II in genetic hypertension. Hypertension 2008; 51: 1637-1642.
100. Marney A, Kunchakarra S, Byrne L et al. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensinconverting enzyme inhibition in humans. Hypertension 2010; 56: 728-733.
101. Tofovic DS, Bilan VP, Jackson EK. Sitagliptin augments angiotensin II-induced renal vasoconstriction in kidneys from rats with metabolic syndrome. Clin Exp Pharmacol Physiol 2010; 37: 689-691.
102. Jackson EK, Zhang M, Liu W et al. Inhibition of renal dipeptidyl peptidase IV enhances peptide YY1-36-induced potentiation of angiotensin IImediated renal vasoconstriction in spontaneously hypertensive rats. J Pharmacol Exp Ther 2007; 323: 431-437.
103. Bergenstal RM, Wysham C, Macconell L et al. Efficacy and safety of exenatide once weekly vs. sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376: 431-439.